JP2011157375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011157375A5 JP2011157375A5 JP2011079933A JP2011079933A JP2011157375A5 JP 2011157375 A5 JP2011157375 A5 JP 2011157375A5 JP 2011079933 A JP2011079933 A JP 2011079933A JP 2011079933 A JP2011079933 A JP 2011079933A JP 2011157375 A5 JP2011157375 A5 JP 2011157375A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- salt
- derivative according
- appetite suppressant
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 239000002830 appetite depressant Substances 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 2
- -1 (3S) -3- hydroxypyrrolidine-1-yl Chemical group 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 2
- DLNKOYKMWOXYQA-IONNQARKSA-N cathine Chemical compound C[C@H](N)[C@@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-IONNQARKSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 206010061428 decreased appetite Diseases 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- WZLQYDXACAEGQZ-UHFFFAOYSA-N 6-[1-[2-[(2,2-diphenylacetyl)-methylamino]-2-phenylethyl]pyrrolidin-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)C(=O)N(C)C(C=1C=CC=CC=1)CN(C1)CCC1OC1OC(C(O)=O)C(O)C(O)C1O WZLQYDXACAEGQZ-UHFFFAOYSA-N 0.000 claims 1
- 206010005052 Bladder irritation Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 206010014020 Ear pain Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 1
- 206010018007 Gastrointestinal stenosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000003840 Opioid Receptors Human genes 0.000 claims 1
- 108090000137 Opioid Receptors Proteins 0.000 claims 1
- 208000007542 Paresis Diseases 0.000 claims 1
- NWAYMPWGUSKQRV-UHFFFAOYSA-N [1-[2-[(2-oxo-3,3-diphenylpropyl)amino]-2-phenylethyl]pyrrolidin-3-yl] hydrogen sulfate Chemical compound C1CN(CC1OS(=O)(=O)O)CC(C2=CC=CC=C2)NCC(=O)C(C3=CC=CC=C3)C4=CC=CC=C4 NWAYMPWGUSKQRV-UHFFFAOYSA-N 0.000 claims 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims 1
- 125000005907 alkyl ester group Chemical class 0.000 claims 1
- JHLHNYVMZCADTC-LOSJGSFVSA-N asimadoline Chemical compound C([C@@H](N(C)C(=O)C(C=1C=CC=CC=1)C=1C=CC=CC=1)C=1C=CC=CC=1)N1CC[C@H](O)C1 JHLHNYVMZCADTC-LOSJGSFVSA-N 0.000 claims 1
- 229960003609 cathine Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 229960002179 ephedrine Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229940097043 glucuronic acid Drugs 0.000 claims 1
- 208000008384 ileus Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- DKLYDESVXZKCFI-UHFFFAOYSA-N n,n-diphenylacetamide Chemical class C=1C=CC=CC=1N(C(=O)C)C1=CC=CC=C1 DKLYDESVXZKCFI-UHFFFAOYSA-N 0.000 claims 1
- DIZKGJLRHOCMTP-UHFFFAOYSA-N n-methyl-2,2-diphenylacetamide Chemical group C=1C=CC=CC=1C(C(=O)NC)C1=CC=CC=C1 DIZKGJLRHOCMTP-UHFFFAOYSA-N 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical group C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 1
- 229960000395 phenylpropanolamine Drugs 0.000 claims 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical group OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10259245.4 | 2002-12-17 | ||
| DE10259245A DE10259245A1 (de) | 2002-12-17 | 2002-12-17 | Derivate des Asimadolins mit kovalent gebundenen Säuren |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559717A Division JP5253709B2 (ja) | 2002-12-17 | 2003-11-25 | 共有結合した酸を有するアシマドリンの誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011157375A JP2011157375A (ja) | 2011-08-18 |
| JP2011157375A5 true JP2011157375A5 (enExample) | 2012-10-25 |
Family
ID=32403913
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559717A Expired - Fee Related JP5253709B2 (ja) | 2002-12-17 | 2003-11-25 | 共有結合した酸を有するアシマドリンの誘導体 |
| JP2011079933A Pending JP2011157375A (ja) | 2002-12-17 | 2011-03-31 | 共有結合した酸を有するアシマドリンの誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559717A Expired - Fee Related JP5253709B2 (ja) | 2002-12-17 | 2003-11-25 | 共有結合した酸を有するアシマドリンの誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7385065B2 (enExample) |
| EP (1) | EP1572640B1 (enExample) |
| JP (2) | JP5253709B2 (enExample) |
| AU (1) | AU2003288159B2 (enExample) |
| CA (1) | CA2510167C (enExample) |
| CY (1) | CY1113781T1 (enExample) |
| DE (1) | DE10259245A1 (enExample) |
| DK (1) | DK1572640T3 (enExample) |
| ES (1) | ES2401876T3 (enExample) |
| PE (1) | PE20040910A1 (enExample) |
| PT (1) | PT1572640E (enExample) |
| SI (1) | SI1572640T1 (enExample) |
| TW (1) | TWI335815B (enExample) |
| WO (1) | WO2004054970A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10259245A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
| CA2544245A1 (en) * | 2003-10-30 | 2005-05-26 | Tioga Pharmaceuticals, Inc. | Use of selective opiate receptor modulators in the treatment of neuropathy |
| EP2636407A3 (en) | 2007-03-30 | 2013-11-06 | Tioga Pharmaceuticals, Inc. | Kappa-opiate agonists for the treatment of diarrhea-predominant and alternating irritable bowel syndrome |
| WO2014210436A2 (en) * | 2013-06-28 | 2014-12-31 | Nektar Therapeutics | Kappa opioid agonists and uses thereof |
| CA3047325A1 (en) | 2016-12-21 | 2018-06-28 | Tioga Pharmaceuticals Inc. | Solid pharmaceutical formulations of asimadoline |
| WO2019122361A1 (en) * | 2017-12-22 | 2019-06-27 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis |
| EP3932390A1 (en) | 2020-07-02 | 2022-01-05 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Topical gel formulation containing asimadoline |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4760069A (en) | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
| US4889860A (en) | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
| US5300687A (en) | 1991-07-18 | 1994-04-05 | Ortho Pharmaceutical Corporation | Trifluoromethylbenzylphosphonates useful in treating osteoporosis |
| DE4215213A1 (de) * | 1992-05-09 | 1993-11-11 | Merck Patent Gmbh | Arylacetamide |
| DE4425071C2 (de) | 1994-07-15 | 1996-08-29 | Degussa | Verfahren zur Herstellung optisch aktiver Pyrrolidine mit hoher Enantiomerenreinheit |
| DE19523502A1 (de) | 1995-06-28 | 1997-01-02 | Merck Patent Gmbh | Kappa-Opiatagonisten für entzündliche Darmerkrankungen |
| DE19531464A1 (de) | 1995-08-26 | 1997-02-27 | Merck Patent Gmbh | N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid |
| US6303611B1 (en) * | 1996-03-08 | 2001-10-16 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
| DE19647538A1 (de) | 1996-11-16 | 1998-05-20 | Merck Patent Gmbh | Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[1-phenyl-2-(-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid |
| JP2001506652A (ja) * | 1996-12-16 | 2001-05-22 | アルコン ラボラトリーズ，インコーポレイテッド | 眼の痛みを治療するためのκオピオイド・アゴニストの局所使用 |
| BR9814484A (pt) | 1997-12-24 | 2000-10-10 | Vertex Pharma | "pró-drogas de inibidores de aspartil protease" |
| DE19827633A1 (de) | 1998-04-20 | 1999-10-21 | Merck Patent Gmbh | Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid |
| DE19849650A1 (de) | 1998-10-29 | 2000-05-04 | Merck Patent Gmbh | Kappa-Opiatagonisten für die Behandlung des Irritable Bowel Syndroms (IBS) |
| US20020025948A1 (en) | 2000-06-23 | 2002-02-28 | Banks Bernard Joseph | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| GB0015562D0 (en) | 2000-06-23 | 2000-08-16 | Pfizer Ltd | Heterocycles |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6569449B1 (en) | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
| PT1355644E (pt) * | 2001-01-26 | 2006-11-30 | Schering Corp | Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia |
| DE10116978A1 (de) * | 2001-04-05 | 2002-10-10 | Merck Patent Gmbh | Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase |
| WO2003048113A1 (en) | 2001-11-30 | 2003-06-12 | Sepracor Inc. | Tramadol analogs and uses thereof |
| CN100411618C (zh) | 2002-05-17 | 2008-08-20 | 迪欧加药品公司 | 有效的选择性阿片受体调制剂化合物的用途 |
| DE10259245A1 (de) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Derivate des Asimadolins mit kovalent gebundenen Säuren |
-
2002
- 2002-12-17 DE DE10259245A patent/DE10259245A1/de not_active Withdrawn
-
2003
- 2003-11-25 DK DK03780043.0T patent/DK1572640T3/da active
- 2003-11-25 SI SI200332242T patent/SI1572640T1/sl unknown
- 2003-11-25 JP JP2004559717A patent/JP5253709B2/ja not_active Expired - Fee Related
- 2003-11-25 CA CA2510167A patent/CA2510167C/en not_active Expired - Fee Related
- 2003-11-25 EP EP03780043A patent/EP1572640B1/de not_active Expired - Lifetime
- 2003-11-25 PT PT37800430T patent/PT1572640E/pt unknown
- 2003-11-25 WO PCT/EP2003/013206 patent/WO2004054970A1/de not_active Ceased
- 2003-11-25 ES ES03780043T patent/ES2401876T3/es not_active Expired - Lifetime
- 2003-11-25 AU AU2003288159A patent/AU2003288159B2/en not_active Ceased
- 2003-11-25 US US10/539,256 patent/US7385065B2/en not_active Expired - Fee Related
- 2003-12-10 PE PE2003001254A patent/PE20040910A1/es not_active Application Discontinuation
- 2003-12-11 TW TW092135046A patent/TWI335815B/zh not_active IP Right Cessation
-
2007
- 2007-04-02 US US11/732,309 patent/US20070179098A1/en not_active Abandoned
-
2008
- 2008-06-02 US US12/131,836 patent/US7915228B2/en not_active Expired - Fee Related
-
2011
- 2011-03-31 JP JP2011079933A patent/JP2011157375A/ja active Pending
-
2013
- 2013-02-04 CY CY20131100097T patent/CY1113781T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210244671A1 (en) | Monolithic tablets based on carboxyl polymeric complexes for controlled drug release | |
| JP6612200B2 (ja) | 抗炎症性の置換シクロブテンジオン化合物のコリン塩 | |
| CN103096895B (zh) | 烟酸模拟物及其使用的方法 | |
| JP2010518122A5 (enExample) | ||
| RU2017115925A (ru) | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе | |
| JP2013526482A5 (enExample) | ||
| JP2014520842A (ja) | モンテルカストおよびリボセチリジン配合のカプセル製剤 | |
| JP2024540183A5 (enExample) | ||
| JP6163165B2 (ja) | レボセチリジンまたはその医薬的に許容される塩およびモンテルカストまたはその医薬的に許容される塩を含む経口投与用安定医薬製剤 | |
| JP2010534236A5 (enExample) | ||
| JP2010515682A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2015522603A5 (enExample) | ||
| JP2008533127A5 (enExample) | ||
| MY151230A (en) | Novel method | |
| WO2006000903A2 (en) | Use of reboxetine for the treatment of pain | |
| JP2016520556A (ja) | Ｎｓａｉｄ投与並びに関連する組成物、方法及びシステム | |
| JP2014506230A5 (enExample) | ||
| TW201201816A (en) | Hypersulfated glucopyranosides | |
| EP2809305B1 (en) | Bilayer tablet formulations of flurbiprofen and glucosamin | |
| CA2510167A1 (en) | Derivatives of asimadoline with covalently bonded acids | |
| EP3238713A1 (en) | Pharmaceutical compositions of flurbiprofen and tramadol | |
| EP3173077B1 (en) | Tablet formulations of nimesulide and thiocolchicoside | |
| US20140363508A1 (en) | Pharmaceutical formulations of flurbiprofen and glucosamin | |
| JP2011157298A (ja) | 胃潰瘍治療剤 |